|  |
| --- |
| **WOUND ASSESSMENT*** Identify and manage underlying aetiology
* Optimise control of additional factors that can impede wound healing such as nutrition, smoking, comorbid conditions.
* Determine long and short-term goals of care
* Develop a plan of care in consultation with the client or carer and evaluate its effectiveness
 |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Exudate Level** | **Eplitheliating**Aim-Moisture balance | **Granulating**Aim-Moisture balance | **Necrotic slough**Aim-RehydrateAutolysis | **Infected wounds**Aim-Reduce bacterial burden |
| **Low** | * Low adherent low absorbency dressing
* Semi permeable film
* Tulle gras
* Hydrocolloid

*Fragile skin** Silicone tulle/foam
 | * Tulle gras
* Hydrocolloid
* Hydrogel
* Silicone tulle/foam

*Fragile skin** Silicone tulle/foam
 | * Hydrocolloid
* Hydrogel
 | * PHMB solution/gel
* PVP I Tulle gras
* Cadexomer iodine paste
* Wound honey calcium alginate
* DACC hydrogel
* Tea tree gel
* Hypertonic saline
* Silver impregnated
 |
| **Moderate** | * Gelling fibre
* Foam
* Absorbent dry pad

*Fragile skin** Silicone foam
 | * Gelling fibre
* Foam
* Absorbent dry pad
* Single use topical negative pressure

*Fragile skin** Silicone foam
 | * Foam
* Cadexomer iodine ointment
* Hypertonic saline

*Fragile skin** Silicone foam
 | * PHMB solution
* Cadexomer iodine ointment/powder
* Wound honey calcium alginate
* Silver impregnated
* Hypertonic saline
* DACC compress
 |
| **Heavy** | Secondary dressing as required | * Gelling fibre
* Foam
* Multi-layered silicone
* Ostomy/drainage bag
* Topical negative pressure
* Absorbent dry pad
* Super absorbent dry dressing
 | * Foam
* Multi-layered silicone
* Ostomy/drainage bag
* Absorbent dry pad
 | * PHMB solution
* Cadexomer iodine powder
* Wound honey alginate
* Silver impregnated
* Hypertonic saline
* DACC compress
* Topical negative pressure
 |
| **Additional interventions** |  |  | Refer to AWAS for low frequency ultrasonic or sharp debridement | Medical reviewWound swab +/- systemic antibiotics |
| Malodour: Charcoal/odour absorbing dressings (consider infection and need for debridement if indicated).Exposed bone/tendon: Maintain moisture balance/viability. Gelling fibre, calcium alginate, hydrogelFriable bleeding wounds: Achieve haemostasis: calcium alginate or stomahesive powderCavity wounds-refer to packing protocol BC-CP-0029 |

|  |
| --- |
| **Complex, non-healing wounds:** liaise with CON/CNCM, AWAS referral (NP), Medical governance review. Refer to escalation process for wound management BC-WI-0196.Refer to BC-GLCL-0010 Wound product guideline Western Australia specific for product descriptions brand names. |

|  |
| --- |
| **PREVIOUS PRODUCTS USED** |
| **KNOWN ALLERGIES** |
| **WOUND****LOCATION** | **WOUND** **LOCATION** |
| **CARE PLAN 1 – REPORTABLE ITEMS** | **CARE PLAN 2 – REPORTABLE ITEMS** |
| * Any changes in the client/carer’s general condition or ability to manage
* Signs and symptoms of local and systemic infection
* Any change in the wound or surrounding skin
 | * Any changes in the client/carer’s general condition or ability to manage
* Signs and symptoms of local and systemic infection
* Any change in the wound or surrounding skin
 |
| **SPECIFIC REPORTABLE ITEMS** | **SPECIFIC REPORTABLE ITEMS** |
|  |  |
| **DATE** | **FREQUENCY** | **NAME/DESIGNATION/ SIGNATURE** | **DATE** | **FREQUENCY** | **NAME/DESIGNATION/ SIGNATURE** |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
| **SHORT TERM GOAL** | **SHORT TERM GOAL** |
|  |  |
|  |  |
|  |  |
| **PROCEDURE** | **PROCEDURE** |
| **Cleanse with** | **Cleanse with** |
|  |  |
|  |  |
| **PRIMARY DRESSING** | **PRIMARY DRESSING** |
|  |  |
|  |  |
|  |  |
| **SECONDARY DRESSING** | **SECONDARY DRESSING** |
|  |  |
|  |  |
|  |  |
| **FIXATION/BANDAGING** | **FIXATION/BANDAGING** |
|  |  |
|  |  |
|  |  |
| **EDUCATION** [ ]  | **EDUCATION** [ ]  |
| Client received education in relation to goal, wound management products and their action. | Client received education in relation to goal, wound management products and their action.. |
| **CLIENT SPECIFIC (Posture, Aids)** | **CLIENT SPECIFIC (Posture, Aids)** |
|  |  |
|  |  |
| **CONSENT** | **CONSENT** |
| Treatment, rationale and ongoing management discussed with client/carer and consent obtained. [ ]  | Treatment, rationale and ongoing management discussed with client/carer and consent obtained. [ ]  |
| **RN REVIEW DATE** | **RN REVIEW DATE** |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
| **PROBLEM OUTCOME/PROBLEM VARIANCE** | **PROBLEM OUTCOME/PROBLEM VARIANCE** |
| PURAM Review [ ]  N/A [ ]  | PURAM Review [ ]  N/A [ ]  |
|  |  |
|  |  |
| **NAME/PROVIDER** | **NAME/PROVIDER:**  |
| **SIGNATURE DATE** | **SIGNATURE: DATE** |
| **Each change in Care Plan must be supported by documented assessment and rationale** |

|  |
| --- |
| **PREVIOUS PRODUCTS USED** |
| **KNOWN ALLERGIES** |
| **WOUND****LOCATION** | **WOUND** **LOCATION** |
| **CARE PLAN 1 – REPORTABLE ITEMS** | **CARE PLAN 2 – REPORTABLE ITEMS** |
| * Any changes in the client/carer’s general condition or ability to manage
* Signs and symptoms of local and systemic infection
* Any change in the wound or surrounding skin
 | * Any changes in the client/carer’s general condition or ability to manage
* Signs and symptoms of local and systemic infection
* Any change in the wound or surrounding skin
 |
| **SPECIFIC REPORTABLE ITEMS** | **SPECIFIC REPORTABLE ITEMS** |
|  |  |
| **DATE** | **FREQUENCY** | **NAME/DESIGNATION/ SIGNATURE** | **DATE** | **FREQUENCY** | **NAME/DESIGNATION/ SIGNATURE** |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
| **SHORT TERM GOAL** | **SHORT TERM GOAL** |
|  |  |
|  |  |
|  |  |
| **PROCEDURE** | **PROCEDURE** |
| **Cleanse with** | **Cleanse with** |
|  |  |
|  |  |
| **PRIMARY DRESSING** | **PRIMARY DRESSING** |
|  |  |
|  |  |
|  |  |
| **SECONDARY DRESSING** | **SECONDARY DRESSING** |
|  |  |
|  |  |
|  |  |
| **FIXATION/BANDAGING** | **FIXATION/BANDAGING** |
|  |  |
|  |  |
|  |  |
| **EDUCATION** [ ]  | **EDUCATION** [ ]  |
| Client received education in relation to goal, wound management products and their action. | Client received education in relation to goal, wound management products and their action.. |
| **CLIENT SPECIFIC (Posture, Aids)** | **CLIENT SPECIFIC (Posture, Aids)** |
|  |  |
|  |  |
| **CONSENT** | **CONSENT** |
| Treatment, rationale and ongoing management discussed with client/carer and consent obtained. [ ]  | Treatment, rationale and ongoing management discussed with client/carer and consent obtained. [ ]  |
| **RN REVIEW DATE** | **RN REVIEW DATE** |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
| **PROBLEM OUTCOME/PROBLEM VARIANCE** | **PROBLEM OUTCOME/PROBLEM VARIANCE** |
| PURAM Review [ ]  N/A [ ]  | PURAM Review [ ]  N/A [ ]  |
|  |  |
|  |  |
| **NAME/PROVIDER** | **NAME/PROVIDER:**  |
| **SIGNATURE DATE** | **SIGNATURE: DATE** |
| **Each change in Care Plan must be supported by documented assessment and rationale** |

**GUIDELINES FOR LOWER LEG COMPRESSION BANDAGING ACCORDING TO AETIOLOGY**

|  |  |  |  |
| --- | --- | --- | --- |
| **0.5 – 0.69** | **0.7 – 0.8** | **0.8 – 1.2** | **> 1.2** |
| Mixed Arterial/VenousTrial of bandage according to tolerance | Mixed Venous/ArterialTrial of bandage according to tolerance | Absence of Arterial Disease (Venous)Trial of bandage according to tolerance | Possibly CalcifiedTrial of bandage according to tolerance |
| Light compression (16-18mmHg) | Light to moderate compression (25mmHg) | Moderate to high compression (30 – 40 mmHg) | Moderate to low compression (30 – 20 mmHg) |
| Padding bandage eg Soffban® (0mmHg) |  | **3-layer system**Padding bandage eg Soffban® (0mmHg) |  | **4-layer system**Padding bandage eg Soffban®(0mmHg) |  | **3-layer system**Padding bandage eg Soffban® (0mmHg) |  |
| Lastodur® Light (figure 8 application 16-18mmHg) |  | White crepe (0mmHg) |  | White crepe (0mmHg) |  | White crepe (0mmHg) |  |
| +/- Tubular elasticated bandage eg Tubigrip®Remove tubular elasticated bandage at night (if client/carer unable to remove use tubular retention bandage eg Tubifast®) |  | Cohesive bandage Coban® (22mmHg) | https://www.alphasport.com.au/uploaded/thumbnails/db_file_img_969_800x700.jpg | Light elastic bandage Lastodur® (figure 8 application 16-18mmHg) |  | Cohesive bandage Coban® (22mmHg) | https://www.alphasport.com.au/uploaded/thumbnails/db_file_img_969_800x700.jpg |
|  |  |  |  | Cohesive bandage Coban® (22mmHg) | https://www.alphasport.com.au/uploaded/thumbnails/db_file_img_969_800x700.jpg |  |  |
| **Other Bandaging Options (requires CON, CNCM or NP approval)** |
| Tubular elasticated bandage e.g. Tubigrip® \* (may need to remove at night)Padding and crepe bandage required |  | Coban Lite® (2-layer system)or | http://multimedia.3m.com/mws/mediawebserver?mwsId=SSSSSuH8gc7nZxtUOxmxlY_vevU9eChshvTSevTSeSSSSSS--&boundedSize=1500 | PütterPro 2® (2-layer system) |  | Coban Lite® (2-layer system) | http://multimedia.3m.com/mws/mediawebserver?mwsId=SSSSSuH8gc7nZxtUOxmxlY_vevU9eChshvTSevTSeSSSSSS--&boundedSize=1500 |
|  |  | Shaped tubular elasticated bandage eg Tubigrip® \*Padding and crepe bandage required | https://cdn.totaldiabetessupply.com/media/product-images/1474.jpg |  |  |  |  |
| **Prevention and Post Healing** (continuing bandaging for 2 weeks post healing) |
| Compression StockingsClass 1 (20-30mmHg) | Compression StockingsClass 1 (20-30mmHg) | Compression StockingsClass 2 (30-40mmHg) | Compression StockingsClass 1 (20-30mmHg) |